-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Category Archives: Events
Latest From Events
Managed Entry Trumps Risk Sharing
Since 2000, pharmaceu-tical and biotech companies have engaged in agreements with government and private payers across the world to gain market access for their innovative drugs despite struggles to qualify for formal reimbursement criteria, such as the cost effectiveness threshold from NICE in the UK. These agreements, usually referred to as “risk sharing” agreements, have had a wide variety of structures but usually do not involve any sharing of risk, as the name misleadingly suggests. Read More >
Natalie Ng wins the International BioGENEius Challenge
Today, Cupertino Junior Natalie Ng won the International BioGENEius Challenge, the premier competition for high school students that recognizes outstanding research in biotechnology. Natalie’s research in breast cancer and biomarkers helped her stand out from the 13 other finalists from across the U.S., Canada and Australia competing for the Challenge’s top prize, a $7,500 cash award. The winner was named during the 2013 BIO International Convention’s keynote luncheon. The International BioGENEius Challenges is one of Read More >
Getting to Know Women in Bio
We caught up with Women In Bio’s President, Phyllis Dillinger, to learn more about the group’s philosophy, agenda, programming and networking events Tell me about your organization and why it was founded. A few smart, entrepreneurial women in greater Washington, D.C. started Women In Bio in 2002 to meet like-minded women in the biosciences who could provide support for building their businesses. Since then, we’ve expanded our mission to include mentoring, networking and development opportunities Read More >
BIO One-On-One Partnering Kicks Off!
Partnering kicked off this today at the Business Forum at the 2013 BIO International Convention, and the numbers so far show that we have a strong week ahead of us. Over 130,000 partnering meeting requests have been requested Almost 22,000 meetings are already scheduled 4,900 of those meetings are exhibitor partnering meetings For a more in-depth look at the types of companies being represented at and stats on how many partnering meetings are taking place, check out this interview with Read More >
Expanding Access to Orphan Drugs
At present many orphan diseases do not have any licensed treatments, and for those conditions where there is a therapy, it is often the only therapy in the class that is available. However, this is not always the case. In the field of blood-plasma proteins, therapies to treat hemophilia, alpha-1 deficiency and primary immune deficiencies have multiple innovator versions in a therapeutic class. Often one product in the class has received an orphan designation and Read More >
